SynAct Pharma AB (FRA:8F8)

Germany flag Germany · Delayed Price · Currency is EUR
1.884
-0.156 (-7.65%)
At close: Jan 5, 2026
94.83%
Market Cap110.47M
Revenue (ttm)n/a
Net Income (ttm)-9.61M
Shares Outn/a
EPS (ttm)-0.20
PE Ration/a
Forward PE82.50
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume51
Open1.976
Previous Close2.040
Day's Range1.884 - 2.000
52-Week Range0.743 - 2.320
Betan/a
RSI56.28
Earnings DateFeb 18, 2026

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2012
Employees 6
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 8F8
Full Company Profile

Financial Performance

Financial numbers in SEK Financial Statements

News

There is no news available yet.